Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 12/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
| ▸ | MMP16 | P51512 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107744 | 0.85 | GCK (0.56) | GCKKCNH2 | |
| SCHEMBL2669019 | 0.85 | ALDH1A1 (0.43) | GCKKCNH2FFAR1 | |
| SCHEMBL12594271 | 0.83 | GCK (0.53) | GCKKCNH2 | |
| SCHEMBL1107501 | 0.83 | GCK (0.58) | GCKKCNH2 | |
| SCHEMBL5122670 | 0.83 | MMP2 (0.51) | FFAR1MMP2MMP9MMP8MMP12 | |
| SCHEMBL2668841 | 0.82 | GCK (0.53) | GCKKCNH2 | |
| SCHEMBL1107721 | 0.82 | GCK (0.55) | GCKKCNH2 | |
| SCHEMBL2668144 | 0.81 | GCK (0.46) | GCKKCNH2 | |
| SCHEMBL5123329 | 0.81 | ALDH1A1 (0.44) | FFAR1MMP2MMP9MMP8MMP12 | |
| SCHEMBL5132239 | 0.81 | ALDH1A1 (0.44) | FFAR1MMP2MMP9MMP8MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008005964-A2 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |